Literature DB >> 22652728

Role of vitamin D receptor activators in peritoneal dialysis.

J Bover, M J Lloret, I DaSilva, M Furlano, M Díaz, A Herreros, M Cozzolino, J Ballarín.   

Abstract

Chronic kidney disease (CKD), including patients on peritoneal dialysis (PD), is linked to an important increase in mortality risk. Within the new systemic term CKD-MBD, alterations in vitamin D metabolism are also included. Many adverse events have been associated with vitamin D deficiency or lack of vitamin D receptor (VDR) activation both in the general population and CKD patients, and these associations seem to be maintained in PD patients. Particularities of PD in vitamin D metabolism, calcium balance, low PTH levels and the high prevalence of adynamic bone disease are discussed. We also review the associations of clinical or survival benefits with vitamin D supplementation, VDR or selective VDR activation, although they are low-graded and most of them obtained from HD databases. Nevertheless, we think that the combined approach to secondary hyperparathyroidism seems also to be appropriate in PD patients, and vitamin D (native plus VDR or selective VDR activation) seem an important part of the required integral approach. The later may provide additional benefits but definitive prove is still lacking.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22652728     DOI: 10.1159/000337832

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  2 in total

1.  Levels of vitamin D receptor and CYP24A1 in patients with end-stage renal disease.

Authors:  Jia-Jun Ye; Tian-Biao Zhou; Yun-Fang Zhang; Qi Wang; Yan-Yan Su; Jia-Min Tang; Hong-Yan Li
Journal:  Afr Health Sci       Date:  2016-06       Impact factor: 0.927

Review 2.  Chronic Kidney Disease-Mineral Bone Disorder in the Elderly Peritoneal Dialysis Patient.

Authors:  James Goya Heaf
Journal:  Perit Dial Int       Date:  2015-11       Impact factor: 1.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.